Board of Directors
Insmed's management team is complemented by the stewardship of our Board of Directors. We have assembled a group of individuals who bring impressive business and medical credentials to our company. Together, we all share the same passion focusing our business approach on the patients who are looking for safe and effective medicines to fight their uncommon, but serious medical conditions.
Donald J. Hayden, Jr.
Chairman of the Board
Mr. Hayden serves as Chairman of the Board, initiating his role following Insmed's merger with Transave in 2010. He had previously served as Executive Chairman of Transave since April 2006. Mr. Hayden also currently serves as Lead Independent Director of Amicus Therapeutics and Director of Otsuka Pharmaceuticals. He also serves in Board roles for several privately held companies, including Executive Chairman of Azelon Pharmaceuticals, Chairman of Vitae Pharmaceuticals and Satori Pharmaceuticals, and Director of Nora Therapeutics. Mr. Hayden is also a senior advisor to Prospect Venture Partners, a venture capital firm. From 1981 to 2006, he had a 25-year career with Bristol-Myers Squibb Company, where he served in key executive roles such as President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development. Mr. Hayden holds a BA from Harvard University and an MBA from Indiana University.
Alfred F. Altomari
Mr. Altomari was elected to Insmed's Board of Directors in August 2012. Since October 2010, Mr. Altomari has served as President and Chief Executive Officer of Agile Therapeutics, where he is also a member of the company's Board of Directors. Prior to being named President and CEO, he served as Agile's Executive Chairman. Before joining Agile, Mr. Altomari held multiple senior management positions over a five-year period at Barrier Therapeutics. In 2008, in his role as Chief Executive Officer, and as a member of the company's Board of Directors, Mr. Altomari completed the successful sale of the company to GlaxoSmithKline/Stiefel Laboratories. Prior to joining Barrier, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson from 1982 to 2003. He completed his tenure with Johnson & Johnson as General Manager of Ortho Neutrogena, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. Mr. Altomari received a Masters in Business Administration from Rider University and his Bachelor of Science from Drexel University.
Steinar J. Engelsen, MD
Dr. Engelsen has been a member of Insmed's Board since our inception in November 1999 and was a director of Insmed Pharmaceuticals, our predecessor entity, from 1998 to 1999. Since November 1996, Dr. Engelsen has been a partner of Teknoinvest Management AS, a venture capital firm based in Norway. From 1989 until October 1996, Dr. Engelsen held various management positions within Hafslund Nycomed AS, a pharmaceutical company based in Europe, and affiliated companies. He was responsible for therapeutic research and development, most recently serving as Senior Vice President, Research and Development of Nycomed Pharma AS from January 1994 until October 1996. In addition, from January to November 2000, Dr. Engelsen was acting Chief Executive Officer of Centaur Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Engelsen also served as Chairman of the Board of Directors of Centaur. Dr. Engelsen received his MSc in Nuclear Chemistry and his MD from the University of Oslo, and is a Certified European Financial Analyst.
Richard S. Kollender
Mr. Kollender joined Insmed’s Board of Directors in January 2011, having served on the Board for Transave since 2007. Mr. Kollender is a Partner at Quaker Partners, a venture capital and growth equity firm investing in life science companies. Previously, he worked at GlaxoSmithKline where he held positions in sales, marketing and worldwide business development. Mr. Kollender also served as an investment manager at S.R. One and was a Certified Public Accountant with KPMG with significant emphasis on the healthcare and emerging business sectors. He is a member of both the American and Pennsylvania Institutes of Certified Public Accountants. He serves on the boards of directors of Precision Therapeutics, Rapid Micro Biosystems, NuPathe (Nasdaq: PATH) and Celator Pharmaceuticals. Mr. Kollender holds a BA from Franklin and Marshall College and an MBA and Health Administration & Policy degrees with Honors from the University of Chicago.
Mr. Lewis joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Mr. Lewis has more than 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the US and internationally. He is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). During his tenure at Aegerion, Mr. Lewis played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications enabling Aegerion to go public in one of the best performing IPOs of 2010. Prior to Aegerion, Mr. Lewis spent more than 10 years working in the US and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. During his time in banking, he was involved in a broad range of domestic and international capital raising and advisory work valued at more than $20 billion. Mr. Lewis began his career as an Operations Officer with the Central Intelligence Agency. He earned a JD and MBA from Case Western Reserve University and a BA with Honors from Oberlin College.
Melvin Sharoky, MD
Dr. Sharoky was Insmed's Chairman of the Board from June 15, 2009 to December 1, 2010 and has been a member of the Insmed Board since May 2001. From March 2007 to December 2007, he was a consultant with Somerset Pharmaceuticals, a research and development pharmaceutical company which markets Eldepryl for the treatment of patients with late stage Parkinson's disease and developed EMSAM® for major depressive disorder, which is licensed to Bristol-Myers Squibb. From January 2002 until March 2007, he was President and CEO of Somerset Pharmaceuticals, Inc. He previously served as President of Somerset Pharmaceuticals from July 1995 to June 2001. From June 2001 to January 2002, Dr. Sharoky was retired. From July 1995 through January 1998, Dr. Sharoky was President of Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, and from February 1993 to January 1998 he was also President and Chief Executive Officer of its wholly-owned subsidiary, Circa Pharmaceuticals, Inc., which develops, manufactures and markets solid dosage generic pharmaceutical products to wholesale distributors. Dr. Sharoky joined Circa Pharmaceuticals in July 1988 as Medical Director, served as Senior Vice President and Director of Research and Development from April 1991 to August 1992, and as Executive Vice President and Director of Research and Development from August 1992 to January 1993. Prior to this, from February 1986 to June 1988, he was Vice President and Chief Medical Officer of Pharmakinetics Laboratories, Inc. Dr. Sharoky received a BA in Biology from the University of Maryland in Baltimore County and an MD from the University of Maryland School of Medicine.
Randall W. Whitcomb, MD
Lead Independent Director
Dr. Whitcomb was appointed Lead Independent Director in May 2012. He has been a member of Insmed's Board since November 2001. Since mid-2007, Dr. Whitcomb has served as a Senior Advisor to the Biopharma investment team of Frazier Healthcare. Dr. Whitcomb was a Founder of Quatrx Pharmaceuticals, Inc., a privately-held, drug development company focusing on discovery, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular areas, where he served as Chief Medical Officer from 2001 to 2006. From 1992 through 2000, he held various management positions with Parke-Davis Pharmaceutical Research, Inc., a division of Warner Lambert Company, serving as Vice President of Drug Development with particular responsibility for the development and approval of products for women's health care, metabolic diseases and diabetes. After the merger of Warner Lambert into Pfizer, Inc., Dr. Whitcomb was Vice-President Global Project Management for Pfizer Global Research and Development. From 1987 through 1992 he was on the faculty of Massachusetts General Hospital and Harvard Medical School. He received his BA degree from Tabor College and his MD degree from the University of Kansas.
*Administered once daily using an optimized eFlow® Electronic Nebulizer (PARI Pharma GmbH).